Russian Journal of ImmunologyRussian Journal of Immunology1028-72212782-7291Russian Society of Immunology19610.31857/S102872210006944-3Research ArticleAPPLICATION OF GENOTYPING CYP3A5 POLYMORPHISM FOR CORRECTING DOSE OF TACROLIMUS IN KIDNEY TRANSPLANTATIONRuzibakiyevaM. R.<p>PhD, Senior Researcher,</p><p>Tashkent</p>malika-ruz@hotmail.comAripovaT. U.<p>MD, Academician of the Academy of Sciences of Uzbekistan, Director of the Institute,</p><p>Tashkent</p>fake@neicon.ruHadzhibaevF. A.<p>D.M.S., Head of Surgery Department,</p><p>Tashkent</p>fake@neicon.ruSharipovV. Kh.<p>MD, Head of the Department of Anaesthesiology and Reanematology,</p><p>Tashkent</p>fake@neicon.ruAzizovaZ. Sh.<p>junior researcher,</p><p>Tashkent</p>fake@neicon.ruInstitute of Human Immunology and Genomics, Academy of Sciences of UzbekistanRepublican Specialized Scientific Center for Emergency Medical Aid of the Ministry of Health of the Republic of Uzbekistan15042019222-14995021305202013052020Copyright © 2019, Ruzibakiyeva M.R., Aripova T.U., Hadzhibaev F.A., Sharipov V.K., Azizova Z.S.2019<p>Currently, according to standard immunosuppression protocols after organ transplantation, tacrolimus is used as a part of immunosuppressive therapy. Along with obtaining the desired immunosuppressive effect, the problem of the development of unwanted adverse reactions to this drug is highly relevant. Pharmacogenetic testing of genotyping of the polymorphism of CYP3A5 G6986A, allows a personalized approach to the selection of the dosing regimen of tacrolimus, may increase the number of patients in whom the concentration of tacrolimus will be within the therapeutic range and will not exceed the acceptable toxicity level.</p>tacrolimusimmunosuppressionkidney transplantationтакролимусиммуносупрессиятрансплантация почки[1. Середенин С. Б. Лекции по фармакогенетике // М.: МИА, 2004. –303 с.][2. Сычев Д. А., Игнатьев И. В., Раменская Г. В., Кукес В. Г. Клиническая фармакогенетика / Под ред. В. Г. Кукеса, Н. П. Бочкова. – М.: ГЭОТАРМЕДИА, 2007. – 248 с.][3. Diasio R. B., Beavers T. L., Carpenter J. T. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity // J. Clin. Invest. – 1988. – Vol. 81. – P. 47–51.][4. Lemoine A., Daniel A., Dennison A., Kiffel L., Lydiane P., Valérie F., Thierry B., Gilles F., Brigitte D., Patrick M., Henri B., Philippe B. FK 506 renal toxicity and lack of detectable cytochrome P-450 3A in the liver graft of a patient undergoing liver transplantation // Hepatology. – 1994. – Vol. 20. – P. 1472–1477.]